Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Propanc Biopharma, Inc. incurred convertible notes of $45,000 with an investor at 8% per annum, which may be increased to 22% in the event of a default maturing July 19, 2024.
- Instrument
- convertible notes
- Principal
- $45,000
- Counterparty
- an investor
- Rate
- 8% per annum, which may be increased to 22% in the event of a default
- Maturity
- July 19, 2024
- Event
- incurrence
Exact text from the filing
On July 19, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on July 28, 2023, pursuant to which the Investor purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $45,000
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Propanc Biopharma, Inc. terminated Equity Line Agreement (effective 2023-07-25).
- Action
- termination
- Agreement
- equity purchase
- Effective
- 2023-07-25
Exact text from the filing
On July 25, 2023, due to a disagreement between the parties relating to the registration of such shares of Common Stock, the Company notified such investor of the termination of the Equity Line Agreement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Propanc Biopharma, Inc. entered into Purchase Agreement valued at $45,000 (effective 2023-07-19).
- Action
- entry
- Agreement
- equity purchase
- Value
- $45,000
- Effective
- 2023-07-19
Exact text from the filing
On July 19, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), which closed on July 28, 2023, pursuant to which the Investor purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $45,000
View on SEC.gov